168 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
9 May 24
Akebia Therapeutics Reports First Quarter 2024 Financial Results
7:03am
(vadadustat) tablets, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of anemia due to chronic kidney disease (CKD … to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
Limitations of Use
VAFSEO has not been shown
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis … that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD
8-K
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
due to chronic kidney disease in adults who have been receiving dialysis for at least three months.
A copy of the press release is attached … to chronic kidney disease in adults who have been receiving dialysis for at least three months.
Item 9.01. Financial Statements and Exhibits.
(d
8-K
EX-99.1
4l42s
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
1b22ly0xstrpq
8 Jan 24
Results of Operations and Financial Condition
8:02am
8-K
EX-99.1
hviqsh72
8 Nov 23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
7:33am
8-K
EX-99.1
qpg6twgc
25 Oct 23
Akebia Receives FDA Acceptance of Resubmission to NDA of
4:06pm
8-K
EX-99.1
9vhqlkj8c4rg11iy
26 Sep 23
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
4:47pm
8-K
EX-99.1
kelahz
25 Aug 23
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
8:14am
8-K
EX-99.1
84q 7ghq7crirjfw
11 Aug 23
Akebia Therapeutics Provides Update on Form 10-Q Filing
7:35am
8-K
au6ogqk50hanvxwi4qwk
18 Jul 23
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
7:47am
8-K
EX-99.1
z6gh7hni0mqeei
18 Jul 23
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
7:47am
8-K
EX-99.1
oti p176l6
7 Jun 23
Regulation FD Disclosure
7:31am